{'fraction_non_alphanumeric': 0.024513947590870666, 'fraction_numerical': 0.00422654268808115, 'mean_word_length': 6.132530120481928, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Streptomycin Induced Ototoxicity in Patient with Brucellosis

Streptomycin is aminoglycoside antibiotic that typically used in tuberculosis, Meniere’s diseases, and other advanced gram-negative bacterial infections. All aminoglycosides have the potential to induce irreversible/reversible ototoxicity and nephrotoxicity. In this report, we present a case of 51-year-old male patient applied to the hospital complaining with weakness, fever, arthralgia and, concomitant prostatitis. The patient diagnosed with Brucellosis and doxycycline+streptomycine was prescribed. On the 5th day of the treatment, he developed vertigo, dizziness, bilaterally ear fullness and in following days hearing loss. Audiogram was revealed that the patient has a bilateral sensorineural hearing loss. Due to suspicion of streptomycin induced vestibulocochlear toxicity, drug treatment was stopped immediately and methylprednisolone treatment (40 mg/day, iv) was administered for ten days to rehabilitate hearing loss. Although there are several case reports for aminoglycoside ototoxicity particularly in cystic fibrosis patients, we depict the first case of aminoglycoside ototoxicity in Brucella patient.